Sort   by:  
 Page size 
UnknownOnce-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial.
Not available
S-EPMC9646993 | biostudies-literature
UnknownOnce-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial.
Not available
S-EPMC12509724 | biostudies-literature
UnknownNeuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial.
Not available
S-EPMC7616346 | biostudies-literature
UnknownDolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.
Not available
S-EPMC9630157 | biostudies-literature
UnknownElective surgery cancellations due to the COVID-19 pandemic: global predictive modelling to inform surgical recovery plans.
Not available
S-EPMC7272903 | biostudies-literature
UnknownPredictors of failure with high-flow nasal oxygen therapy in COVID-19 patients with acute respiratory failure: a multicenter observational study.
Not available
S-EPMC7934982 | biostudies-literature
UnknownHigh-flow nasal oxygen in patients with COVID-19-associated acute respiratory failure.
Not available
S-EPMC7876530 | biostudies-literature
UnknownAwake prone positioning does not reduce the risk of intubation in COVID-19 treated with high-flow nasal oxygen therapy: a multicenter, adjusted cohort study.
Not available
S-EPMC7537953 | biostudies-literature
Sort   by:  
 Page size